Showing results (41-50 of 115) with videos related to

Sort By:
Pageof 12
Transplantation and Cellular Therapy|March 29, 2021
Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell TransplantationEmily C Liang, Lori S Muffly, Parveen Shiraz, et al.
Transplantation and Cellular Therapy|November 9, 2025
Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy StudiesFrederick L Locke, Sarah Nikiforow, Matthew J Frigault, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 4, 2010
Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphomaSally Arai, Renee Letsinger, Ruby M Wong, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 22, 2020
Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel AgentsChristopher Lemieux, Laura J Johnston, Robert Lowsky, et al.
Blood|December 23, 2004
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remissionDavid B Miklos, Haesook T Kim, Katherine H Miller, et al.
American Journal of Hematology|April 25, 2024
Management of post-autologous transplant relapse in patients with T-cell lymphomasOlivier Veilleux, Francisco Socola, Sally Arai, et al.
Blood Advances|January 31, 2024
Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphomaEsther H Nie, Yi-Jiun Su, John H Baird, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2023
Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11Michael D Jain, David B Miklos, Caron A Jacobson, et al.
Blood Advances|February 5, 2024
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7Armin Ghobadi, Javier Munoz, Jason R Westin, et al.
Blood|May 9, 2009
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donorsHolbrook E Kohrt, Brit B Turnbull, Kartoosh Heydari, et al.
Pageof 12